AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-16. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Mitragotri has invented many novel drug delivery technologies, especially in the fields of transdermal, oral and targeted systems. He invented techniques to deliver drugs transdermally using low-frequency ultrasound, pulsed microjet injector, high throughput skin experimentation, skin penetrating peptides and ionic liquids. He also invented intestinal patches and ionic liquids for oral delivery of proteins. Mitragotri also pioneered nanoparticle-enabled cell therapies which use drug-loaded nanoparticles that hitch a ride on red blood cells, monocytes and other circulatory cells for tissue-specific delivery. Mitragotri's technologies are used to develop next generation therapies against diabetes, cancer, psoriasis, hemorrhage, trauma and infections. Mitragotri has published over 400 research publications and is an inventor on over 300 patents/applications. His publications are cited over 81000 times with an h-index of 140. Mitragotri is a member of the US National Academy of Medicine and the US National Academy of Inventors. He is also a member of the US National Academy of Engineering since 2015 for the development, clinical translation, and commercialization of transdermal drug delivery systems. He is also an elected member of The World Academy of Science , American Academy of Arts & Sciences and Indian National Academy of Engineering. He is a co-founder of several companies that are developing products based on his inventions. He received his PhD in chemical engineering at MIT and BS in chemical engineering from the Institute of Chemical Technology.
=== Sexual dimorphism === Several hypothalamic nuclei are sexually dimorphic; i.e., there are clear differences in both structure and function between males and females. Some differences are apparent even in gross neuroanatomy: most notable is the sexually dimorphic nucleus within the preoptic area, in which the differences are subtle changes in the connectivity and chemical sensitivity of particular sets of neurons. The importance of these changes can be recognized by functional differences between males and females. For instance, males of most species prefer the odor and appearance of females over males, which is instrumental in stimulating male sexual behavior. If the sexually dimorphic nucleus is lesioned, this preference for females by males diminishes. Also, the pattern of secretion of growth hormone is sexually dimorphic(for mice); this is why in many species, adult males are visibly distinct sizes from females.
== Neurons == The PVN contains magnocellular neurosecretory cells whose axons extend into the posterior pituitary, parvocellular neurosecretory cells that project to the median eminence, ultimately signalling to the anterior pituitary, and several populations of other cells that project to many different brain regions including parvocellular preautonomic cells that project to the brainstem and spinal cord.
Flaps can be fundamentally classified by their mechanism of movement, the types of tissues present, or by their blood supply. The surgeon generally chooses the least complex type that will achieve the desired effect via a concept known as the reconstructive ladder.
As of 2019, the pathophysiology is largely not understood, although it is increasingly becoming accepted that calcium dysregulation plays a role. Calpain 3 is unique from other calpain proteases in that it is relatively specific to muscle. Calpain 3 is both a protease and a structural protein. As a protease, it cleaves proteins of the sarcomere and cytoskeleton, designating them to be degraded by proteasomes, a part of muscle remodeling. The structural role of calpain 3 is stabilization of the triad protein complexes. A triad protein complex plays a role converting electrical excitation into calcium release, and it is composed of two calcium channels, the ryanodine receptor (RYR1), and the dihydropyridine receptor (DHPR). With calpain 3 mutation, proteins typically found at the triad are reduced, including CaMKII (Ca2+/calmodulin-dependent protein kinase II). Decreased CaMKII activity impairs induction of slow oxidative gene expression, which in turn impairs genes involving the mitochondria and lipid metabolism.
Sources: en.wikipedia.org
=== Remediation === Algae has shown selectivity for strontium in studies, where most plants used in bioremediation have not shown selectivity between calcium and strontium, often becoming saturated with calcium, which is greater in quantity and also present in nuclear waste. Researchers have looked at the bioaccumulation of strontium by Scenedesmus spinosus (algae) in simulated wastewater. The study claims a highly selective biosorption capacity for strontium of S. spinosus, suggesting that it may be appropriate for use of nuclear wastewater. A study of the pond alga Closterium moniliferum using stable strontium found that varying the ratio of barium to strontium in water improved strontium selectivity.
=== Hormone secretion === Two hormones are classically considered as being related to the posterior pituitary: oxytocin and vasopressin. These hormones are created in the hypothalamus and released in the posterior pituitary. After creation, they are stored in neurosecretory vesicles regrouped into Herring bodies before being secreted in the posterior pituitary via the bloodstream.
The Lombard dukes of Friuli ruled Aquileia and the surrounding mainland territory from Cividale. In 774, Charlemagne conquered the Lombard duchy and made it into a Frankish one with Eric of Friuli as duke. In 787, Charlemagne named the priest and master of grammar at the Palace School of Paulinus II, the new patriarch of Aquileia. The patriarchate, despite being divided with a northern portion assigned to the pastoral care of the newly created Archbishopric of Salzburg, would remain one of the largest dioceses. Although Paulinus resided mainly at Cividale, his successor Maxentius considered rebuilding Aquileia. However, the project never came to fruition. While Maxentius was patriarch, the pope approved the Synod of Mantua, which affirmed the precedence of the mainland patriarch of Aquileia over the patriarch of Grado. However, material conditions were soon to worsen for Aquileia. The ruins of Aquileia were continually pillaged for building material. And with the collapse of the Carolingians in the tenth century, the inhabitants would suffer under the raids of the Magyars. By the eleventh century, the patriarch of Aquileia had grown strong enough to assert temporal sovereignty over Friuli and Aquileia. The Holy Roman Emperor gave the region to the patriarch as a feudal possession. However, the patriarch's temporal authority was constantly disputed and assailed by the territorial nobility.
The maximum yield in such kinetic resolutions is 50%, since a yield of more than 50% means that some of wrong isomer also has reacted, giving a lower enantiomeric excess. Such reactions must therefore be terminated before equilibrium is reached. If it is possible to perform such resolutions under conditions where the two substrate- enantiomers are racemizing continuously, all substrate may in theory be converted into enantiopure product. This is called dynamic resolution. In biocatalyzed asymmetric synthesis, a non-chiral unit becomes chiral in such a way that the different possible stereoisomers are formed in different quantities. The chirality is introduced into the substrate by influence of enzyme, which is chiral. Yeast is a biocatalyst for the enantioselective reduction of ketones.
Sources: en.wikipedia.org
In the aftermath, Naram-Sin deified himself as well as posthumously deifying Sargon and Manishtushu but not his uncle Rimush. The echoes of the revolt were reflected in later Sumerian literary compositions such as the Great Revolt against Naram-Sin, "Naram-Sin and the Enemy Hordes" and "Gula-AN and the Seventeen Kings against Naram-Sin".
The American Medical Association (AMA) declared war on Christian Scientists; in 1895 its journal called Christian Science and similar ideas "molochs to infants, and pestilential perils to communities in spreading contagious diseases." Juries were nevertheless reluctant to convict when defendants believed they were helping the patient. There was also opposition to the AMA's effort to strengthen medical licensing laws. Historian Shawn Peters writes that, in the courts and public debate, Christian Scientists and Jehovah's Witnesses linked their healing claims to early Christianity to gain support from other Christians. Vaccination was another battleground. A Christian Scientist in Wisconsin won a case in 1897 that allowed his son to attend public school despite not being vaccinated against smallpox. Others were arrested in 1899 for avoiding vaccination during a smallpox epidemic in Georgia. In 1900 Eddy advised adherents to obey the law, "and then appeal to the gospel to save ...[themselves] from any bad results." In October 1902, after seven-year-old Esther Quimby, the daughter of Christian Scientists, died of diphtheria in White Plains, New York (she had received no medical care and had not been quarantined), the authorities pursued manslaughter charges. The controversy prompted Eddy to declare that "until public thought becomes better acquainted with Christian Science, the Christian Scientists shall decline to doctor infectious or contagious diseases", and from that time the church required Christian Scientists to report contagious diseases to health boards.
Second generation In the 1970s, the first technology was a model of prosthetic-breast with a shell of thin-gauge material and a filler-gel of low-cohesion silicone, which materials improved anatomic function and symmetry (size, appearance, texture) after contouring by the surgeon. In practise, second-generation breast prostheses proved fragile, with greater rates of shell-rupture and filler-leakage. The increased rates-of-incidence of capsular contracture consequently resulted in faulty-product class action-lawsuits by the U.S. government against the manufacturers of thin-gauge-shell breast prostheses. The second technology was a prosthetic breast with a polyurethane foam coating that reduced the rate of incidence of capsular contracture by causing an inflammatory reaction within the implant-socket in order to impede the formation of a capsule of fibrous collagen tissue around the prosthetic breast. In the event, the use of prosthetic breasts coated with polyurethane was discontinued in the U.S. because of the health risk posed by the carcinogenic chemical 2,4-toluene diamine (TDA), a by-product of the chemical breakdown of the polyurethane coating the prosthetic breast. Ultimately, prosthetic breasts coated with polyurethane remain in use in Europe and in South America. The third technology for breast surgery was the double-lumen prosthetic breast, which featured a lumen (a breast prosthesis filled with silicone-gel) contained within a larger lumen (a breast prosthesis filled with saline-solution).
==== Rate of sickle cell disease in Uganda ==== The data compiled on sickle cell disease in Uganda has not been updated since the early 1970s. The deficiency of data is due to a lack of government research funds, even though Ugandans die daily from sickle cell disease. Data shows that the trait frequency of sickle cell disease is 20% of the population in Uganda. It is also estimated that about 25,000 Ugandans are born each year with sickle cell disease and 80% of those people do not live past five years old. Sickle cell disease also contributes 25% to the child mortality rate in Uganda. The Bamba people of Uganda, located in the southwest of the country, carry 45% of the gene, which is the highest trait frequency recorded in the world. The Sickle Cell Clinic in Mulago is the only sickle cell disease clinic in the country and, on average, sees 200 patients a day.
== Dietary requirements == The Food and Nutrition Board (FNB) of the U.S. Institute of Medicine set Recommended Dietary Allowances (RDAs) for essential amino acids in 2002. For leucine, for adults 19 years and older, 42 mg/kg body weight/day; for isoleucine 19 mg/kg body weight/day; for valine 24 mg/kg body weight/day. For a 70 kg (154 lb) person this equates to 2.9, 1.3 and 1.7 g/day. Diets that meet or exceed the RDA for total protein (0.8 g/kg/day; 56 grams for a 70 kg person), meet or exceed the RDAs for branched-chain amino acids.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.